METHODOLOGICAL NOTE

Disclosure of Transfers of Value to HCPs and HCOs

Germany · Austria · Switzerland | Data year 2025

Document details	Information
Reporting entity	Immedica Pharma Germany GmbH
Version	20 July 2026
Publication year	2026
Prepared by	Fabrizio Zucca, General Manager Germany, Austria and Switzerland | fabrizio.zucca@immedica.com

Scope

This single methodological note covers Transfers of Value (ToVs) to recipients based in Germany, Austria and Switzerland. The national code of the recipient's primary professional address or registered office applies.

Contents

1 Definitions

1.1. Recipients

Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) whose primary professional address or registered office is in Germany, Austria or Switzerland.

1.2. Kind of ToVs

Event costs, travel and accommodation, sponsorships, service and consultancy fees and expenses, and donations or grants to HCOs. R&D ToVs are reported separately in aggregate.

2 Disclosure scope

2.1. Products concerned

For 2025, the relevant prescription-only medicinal products were Ravicti®, Loargys® and Akynzeo®.

2.2. Company concerned

Immedica Pharma Germany GmbH, including ToVs made on its behalf or by another Immedica group company for recipients in DACH.

2.3. Excluded ToVs

Excluded are meals, medical samples, exempt informational or medical items, ordinary purchases and sales of medicines, and ToVs solely related to non-prescription medicines.

2.4. ToVs date

The reporting period is 1 January to 31 December 2025. A ToV is allocated to the date on which the payment or benefit was provided.

2.5. Direct ToVs

Included and disclosed against the recipient receiving the payment or benefit directly.

2.6. Indirect ToVs

Included where the final beneficiary can be identified; each ToV is reported once at the final recipient level where possible.

2.7. Non-monetary ToVs

Benefits in kind, including registration, travel and accommodation, are valued at Immedica's actual cost.

2.8. Partial attendance, cancellation and refunds

Refunded costs are excluded. Non-refundable costs attributable to a recipient are disclosed.

2.9. Cross-border activities

ToVs are disclosed in the country of the recipient's primary professional address or registered office, irrespective of which Immedica entity paid them.

2.10. R&D

No reportable R&D ToVs were made in 2025. Any such ToVs would be disclosed in aggregate.

2.11. Voluntary disclosure

All in-scope ToVs are disclosed individually where legally permissible. Where individual disclosure is not legally permissible, including where required consent is absent or withdrawn, the ToVs are disclosed in aggregate under the applicable national rules.

3 Specific considerations

3.1. Country unique identifier

Not applicable for 2025.

3.2. Self-incorporated HCP

A contract with the individual is disclosed as an HCP ToV; a contract with a separate legal entity is disclosed as an HCO ToV, subject to local rules.

3.3. Multi-year agreements

No multi-year agreements affected the 2025 disclosure.

3.4. Country specificities

Immedica follows the EFPIA Code across DACH and, where required, the applicable country-specific transparency rules.

3.5. Quality checks

The data are reconciled against contracts, invoices, expenses and third-party reports and reviewed through different functions before publication in line with Immedica's SOP.

4 Data protection legal basis

4.1. Consent collection

Where consent is required for individual disclosure, it is included in the agreement and documented. If consent is absent, partial or withdrawn, all relevant ToVs for that recipient are disclosed in aggregate.

4.2. Legitimate interests

Individual HCP disclosures were based on the recipient's consent. Immedica did not rely on legitimate interests as the legal basis for such disclosures in 2025.

5 Form of disclosure

5.1. Date of publication

The 2025 disclosure was published on 29 July 2026.

5.2. Disclosure platform

The disclosure report and this methodological note are published at www.immedica.com/en/transparency.

5.3. 5.3 Disclosure language

Disclosure data are published in German for Germany and Austria; in Switzerland, a national language is used where practicable, otherwise English. This combined methodological note is provided in English.

6 Disclosure financial data

6.1. Currency

Amounts are disclosed in EUR for Germany and Austria and CHF for Switzerland. Foreign currencies are converted using the exchange rate applied in Immedica's accounting records.

6.2. VAT included or excluded

Amounts are disclosed excluding VAT where VAT is separately identifiable; otherwise, the actual booked cost is used.

6.3. Calculation rules

Actual costs are reported after refunds and credit notes. Shared costs are allocated equally to identified recipients where an individual allocation is not available.

7 Additional information

Supporting records are retained for at least five years. Published disclosures remain publicly available for at least three years, unless applicable law or the data protection legal basis requires a shorter period.